Overview
- 291 inspections across 235 sites are on record.
- 330 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-20.
At a glance
Inspections
291
Sites
235
Observations
330
Career since
Sep 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Elevar Therapeutics, Inc. | 20 May 2026 | Human Drugs | On file |
| Bristol Myers Squibb | 28 Apr 2026 | Human Drugs | |
| Clinilabs, LLC | 30 Mar 2026 | Human Drugs | |
| Acadia Pharmaceuticals Inc. | 10 Mar 2026 | Human Drugs | |
| Kevin Ma | 28 Jan 2026 | Human Drugs |
Sites inspected
Elevar Therapeutics, Inc.Fort Lee, United States1 insp.
Bristol Myers SquibbPrinceton, United States1 insp.
Clinilabs, LLCEatontown, United States1 insp.
Acadia Pharmaceuticals Inc.Princeton, United States1 insp.
Kevin MaPhiladelphia, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Tyanna N Hadley13 shared
Shirley S Wen10 shared
Mayar M Mussa9 shared
Jay B Shah8 shared
Nina Yang7 shared
Jonee J Mearns6 shared
Maria Estrella5 shared
Denise M Visco4 shared
Jose A Torres3 shared
Peter R Lenahan3 shared
Full investigator report
Get the verbatim findings behind Michael Serrano's 330 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site